Changing careers for 25 years
Celebrating 25 years of the Marketer of the Year competition
PharmaTimes Magazine
PharmaTimes is the UK's leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.
PharmaTimes print and digital versions have a total circulation of 23,184, reaching right across the industry into every company and every function. What's more, our circulation includes 8,000 NHS healthcare professionals: chief pharmacists, medicines management and primary care commissioners.
Click to subscribe to PharmaTimes in paper or print, or to sign up for our industry-leading daily and weekly news elerts.
You can read the latest issue as well as our extensive archive below or get in touch with the editorial or sales team.
Magazine highlights
View more from the latest edition
Trusting pharma
ViiV Healthcare has once again topped the annual PatientView corporate reputation survey. Dr Oleksandr Gorbenko, the company’s director, global patient affairs, explains the company’s views on how pharma should build trust with patients
SmartPeople: Bill Byrom
With over 25 years experience in clinical development and as an eClinical thought leader and strategist, Bill Byrom is an expert on innovating clinical research. Now he has joined CRF Health as vice president of product strategy & innovation to define their product development vision
Nanomedicine: the next breakthrough in oncology?
A look at the exciting breakthroughs in using microscopic interventions to beat cancer
A new era of data protection
The implications of GDPR on pharma and its relationship with healthcare professionals
Walking the patient centric talk
Can pharma prove that being patient centric is more than just a fad?
Pharma and data: Knowledge is power
Sanofi’s Milind Kamkolkar is the first enterprise chief data officer in a major pharmaceutical company, and he has been outspoken about the need for pharma to adapt to the new digital world of AI, real-world evidence and prolific data. We caught up with him on the show floor at eyeforpharma Barcelona 2018
Company focus: Exscientia
With several high-profile collaborations under its belt, Exscientia is bringing AI tech straight to the heart of pharma R&D. We asked the company's founder, Professor Andrew Hopkins, to explain how they’re hoping to make long, expensive drug development a thing of the past
